Absolute Quantification of Amyloid Propagons by Digital Microfluidics by Pfammatter, Manuela et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Absolute Quantification of Amyloid Propagons by Digital Microfluidics
Pfammatter, Manuela; Andreasen, Maria; Meisl, Georg; Taylor, Christopher G; Adamcik, Jozef;
Bolisetty, Sreenath; Sanchez-Ferrer, Antoni; Klenerman, David; Dobson, Christopher M; Mezzenga,
Raffaele; Knowles, Tuomas P J; Aguzzi, Adriano A; Hornemann, Simone
DOI: https://doi.org/10.1021/acs.analchem.7b03279
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-141180
Journal Article
Accepted Version
Originally published at:
Pfammatter, Manuela; Andreasen, Maria; Meisl, Georg; Taylor, Christopher G; Adamcik, Jozef; Bolisetty,
Sreenath; Sanchez-Ferrer, Antoni; Klenerman, David; Dobson, Christopher M; Mezzenga, Raffaele;
Knowles, Tuomas P J; Aguzzi, Adriano A; Hornemann, Simone (2017). Absolute Quantification of
Amyloid Propagons by Digital Microfluidics. Analytical Chemistry, 89(22):12306-12313.
DOI: https://doi.org/10.1021/acs.analchem.7b03279
Full text access provided via ACS AuthorChoice
Analytical Chemistry is published by the American Chemical Society. 1155 Sixteenth
Street N.W., Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works
produced by employees of any Commonwealth realm Crown government in the course
of their duties.
Article
Absolute Quantification of Amyloid Propagons by Digital Microfluidics
Manuela Pfammatter, Maria Andreasen, Georg Meisl, Christopher G. Taylor, Jozef Adamcik,
Sreenath Bolisetty, Antoni Sanchez-Ferrer, David Klenerman, Christopher M. Dobson,
Raffaele Mezzenga, Tuomas P.J. Knowles, Adriano A Aguzzi, and Simone Hornemann
Anal. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.analchem.7b03279 • Publication Date (Web): 03 Oct 2017
Downloaded from http://pubs.acs.org on October 26, 2017
Just Accepted
“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted
online prior to technical editing, formatting for publication and author proofing. The American Chemical
Society provides “Just Accepted” as a free service to the research community to expedite the
dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts
appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been
fully peer reviewed, but should not be considered the official version of record. They are accessible to all
readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered
to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published
in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just
Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor
changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers
and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors
or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
 Absolute Quantification of Amyloid Propagons by Digital Microfluidics 
Manuela Pfammatter,† Maria Andreasen,‡,§ Georg Meisl,‡ Christopher G. Taylor,‡ Jozef Adamcik,┴ 
Sreenath Bolisetty,┴ Antoni Sánchez-Ferrer,┴ David Klenerman,‡ Christopher M. Dobson,‡ Raffaele 
Mezzenga,┴ Tuomas P. J. Knowles,‡,║ Adriano Aguzzi,† and Simone Hornemann†,* 
†Institute of Neuropathology, University of Zurich, CH-8091 Zurich, Switzerland 
‡Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, United Kingdom 
§Interdisciplinary Nanoscience Center (iNANO), Aarhus University, DK-8000 Aarhus, Denmark 
┴Department of Health Sciences and Technology, ETH Zurich, CH-8092 Zurich, Switzerland 
║Cavendish Laboratory, Department of Physics, University of Cambridge, Cambridge CB3 1HE, United Kingdom 
ABSTRACT: The self-replicating properties of numerous proteins into amyloid fibrils is a common phenomenon and underlies 
several neurodegenerative diseases. Because propagation-active fibrils are chemically indistinguishable from innocuous aggregates 
and monomeric precursors, their detection requires measurements of their replicative capacity. Here we present a digital amyloid 
quantitative assay (d-AQuA) with insulin as amyloid model for the absolute quantification of single replicative units, propagons. D-
AQuA is a microfluidics-based technology that performs miniaturized simultaneous propagon-induced amplification chain reac-
tions within hundreds to thousands of picoliter-sized droplets. At limiting dilutions, the d-AQuA reactions follow a stochastic re-
gime indicative of the detection of single propagons. D-AQuA thus enables absolute quantification of single propagons present in a 
given sample at very low concentrations. The number of propagons quantified by d-AQuA was similar to that of fibrillar insulin 
aggregates detected by atomic-force microscopy and to an equivalent microplate-based assay, providing independent evidence for 
the identity of insulin propagons with a subset of morphologically defined protein aggregates. The sensitivity, precision and accura-
cy of d-AQuA renders it suitable to multiple biotechnological and medical applications. 
Digital microfluidic assays have revolutionized quantitative 
biology, as they facilitate the precise and accurate quantifica-
tion of absolute numbers of biomolecules1,2. The use of digital 
microfluidics offers the possibility of performing a very large 
number of individual experiments in small droplet compart-
ments in a short time, yielding the data volumes needed for 
digital data analysis. Microfluidics therefore enables assays 
with higher throughput, greater reliability and sensitivity1,3-5. 
The miniaturization to picoliter (pL)-sized droplets further 
allows for an effective reduction in the consumption of rare 
biological samples, costs, potential contamination, and surface 
effects due to the absence of air-water interfaces1-3. This con-
cept has already transformed several applications in DNA 
technology, including the further development of digital pol-
ymerase chain reaction (dPCR)6,7 to droplet digital PCR 
(ddPCR)8-11, DNA microarrays12,13 and next generation se-
quencing14, as it enables large numbers of parallel experiments 
for absolute quantification of specific targets even at low 
concentrations. Digital microfluidics has also been applied to 
cell-based assays15-17, protein biomarker detection18, isother-
mal amplification chemistries19, studies on amyloid growth20 
and high-throughput applications1. In this paper, we describe 
the extension of digital microfluidics to amyloid amplification 
assays. 
Amyloid amplification assays have recently been developed 
to address the urgent need for reliable and sensitive in vitro 
detection of amyloid aggregates, causing several neurodegen-
erative disorders, including transmissible spongiform encepha-
lopathies, Alzheimer’s, Parkinson’s and many other diseases21-
23, for basic research and for diagnostic applications24-27. These 
diseases are associated with the ability of proteins to self-
assemble into amyloid fibrils in a nucleation-dependent 
polymerization reaction28,29. This process typically follows a 
sigmoidal kinetic progression involving primary nucleation, 
aggregate growth and fibril elongation, along with secondary 
processes, such as fragmentation and surface-induced nuclea-
tion events that serve to amplify the number of aggregates30,31. 
The process of amyloid formation therefore involves the gen-
eration of “propagons”32, defined as all those aggregated spe-
cies, including fibrils, that are able to seed or propagate the 
conversion of monomeric proteins into a higher number of 
active propagons in a template-catalyzed way. 
Amyloid amplification assays are built on the self-
propagation principle, promoting the amplification of minute 
amounts of active pathological species to readily detectable 
levels in the presence of their monomeric counterparts. Assays 
that either use cyclic sonication for efficient amplification, as 
the protein misfolding cyclic amplification (PMCA) assay24, 
or agitation in a microplate, as the real-time quaking-induced 
conversion (RT-QuIC) assay25, have been developed for sensi-
tive detection of prions and prionoids33 in biological 
samples26,27,34. These assays, however, have certain limitations 
with respect to automation and high-throughput applications 
and are, because of their analogue nature, able to measure only 
average concentrations. Digital microfluidics may overcome 
these limitations, because of its ability to perform high num-
bers of pL-sized volume reactions, allowing the precise quan-
tification of absolute numbers of single low-abundance entities 
present in a system. 
Here, we describe the development of a digital amyloid 
quantitative assay, d-AQuA, using droplet-based microfluid-
ics. We demonstrate that d-AQuA represents a powerful 
method for the ultrasensitive detection of single insulin propa-
gons contained in a sample and their absolute quantification. 
D-AQuA also showed a significantly better performance with 
respect to sensitivity, precision and speed than an equivalent 
assay in a microplate. We therefore anticipate that d-AQuA 
holds great potential for advancing a wide range of biotechno-
logical and medical research applications and opens up new 
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 avenues for ultrasensitive and precise high-throughput digital 
diagnostics. 
 
EXPERIMENTAL SECTION 
Materials. Human insulin was purchased from Sigma-
Aldrich (SAFC Biosciences) and used without further purifi-
cation. All chemicals unless otherwise specified were pur-
chased from Sigma-Aldrich. 
Standard fibril sample preparation. Fibrils were assem-
bled in vitro by incubating 1 mM monomeric human insulin in 
a 10 mM HCl water solution at pH 2.0 (HCl, pH 2.0) at 65 °C 
and agitation at 600 rpm for 72 h. Remnant monomer was 
removed by intense washing with HCl (pH 2.0) using Amicon 
centrifugal filters (MWCO 100 kDa; Merck Millipore)35. 
Fibrils were lyophilized and stored at -20 °C until usage. The 
sample was diluted to a concentration of 400 µM (monomer 
equivalents) to yield the standard fibril sample. 
Standard fibril sample characterisation. The standard fi-
bril sample was characterized using atomic force microscopy 
(AFM), dynamic light scattering (DLS), Fourier transform 
infra-red spectroscopy (FTIR), far-UV circular dichroism 
(CD) and a self-propagation activity assay. Details are de-
scribed in SI Materials and Methods. 
Microdroplet device fabrication. Microfluidic flow-
focusing devices (Figure S1) were fabricated using standard 
soft-lithography techniques36. Briefly, the device design was 
patterned on a silicon wafer using SU-8 negative photoresist 
(MicroChem) to produce a negative mold. Microfluidic chan-
nels were cast into poly(dimethylsiloxane) (PDMS; Dow 
Corning Sylgard 184 Silicone Elastomer) on the silicon mold, 
and the PDMS stamp was cured at 65 °C for 150 min before 
peeling off the mold. Channel inlets and outlets were punched 
into the PDMS stamp before oxygen plasma bonding it to a 
glass slide to seal the channels. To make channel walls hydro-
phobic, the device was flushed with the water repellent agent 
Aquapel (PPG Industries) for 30 min before washing with 
isopropanol and then blow-drying with a nitrogen stream. 
D-AQuA assay. Lyophilized insulin was dissolved in HCl 
(pH 2.0) at a concentration of 6 mg mL-1 and filtered (50 kDa 
Amicon centrifugal filters; Millipore UFC505096) to remove 
higher molecular weight species. The protein was dissolved to 
a final assay concentration of 400 µM in HCl (pH 2.0) con-
taining 0.1 M GdmCl and 40 µM Thioflavin (ThT). Serial 10-
fold dilutions of the standard fibril sample were prepared in 
HCl (pH 2.0) and added to the reaction mixture immediately 
before encapsulating the mixture into microdroplets. Negative 
controls were incubated with the same volume of HCl (pH 
2.0) instead of fibrils. Amplification reactions were encapsu-
lated into water-in-oil-emulsions using a microfluidic device 
with flow focusing geometry. The sample containing mono-
meric substrate, fibrils and ThT was injected into the middle 
inlet on the chip at a flow rate of 200 µL h-1. The carrier oil 
phase made of fluorinated FC-40 (Sigma) with 4% (w/v) 
triblock co-polymer (ABA) surfactant (where A is a perfluori-
nated poly(propylene oxide) block and B a poly(ethylene 
oxide) block, synthesized as previously described37) was in-
jected into the outer inlet at a flow rate of 300 µL h-1 to gener-
ate droplets with a radius of ~25 µm (volume ~65 pL). Fluid 
flow rates were controlled with a Cetoni neMESYS syringe 
pump (Cetoni GmbH). Between 500 and 1400 replicate drop-
lets were collected per dilution at the outlet into Rectangular 
Boro Silicate capillaries (CM Scientific), and the capillaries 
were sealed with wax plugs to prevent sample evaporation. 
Before imaging the capillaries containing samples at different 
fibril dilutions, capillaries were aligned on a glass slide for 
amplification and imaging. The aligned capillaries were placed 
on the automated motorized stage of a custom-built epifluo-
rescence laser microscope (Figure S1) and covered with a 
hotplate heated to 65 °C to induce amplification. To track 
aggregate formation within the droplets, fluorescent images 
were acquired every 15 min for approximately 24 h using laser 
excitation at 445 nm (diode laser (MLD445, Cobolt)). Individ-
ual droplets were identified manually, and the average intensi-
ty of the droplet area was extracted for all frames. The bright-
ness of the images of the 102 capillary in Figure 3a was mod-
erately adjusted to account for minor differences in brightness 
arising from imaging on different frames of the automated-
stage laser (for original figure see Figure S4). Fluorescent 
traces in Figure 3b were cut after dropping once having 
reached plateau. 
Microplate amyloid amplification assay. Lyophilized in-
sulin was dissolved in HCOOH (pH 3.0) at a concentration of 
6 mg mL-1 and filtered using 50 kDa Amicon Ultra centrifugal 
filters (Millipore, Prod.No. UFC505096). The protein was 
dissolved to a final concentration of 2 µM in 0.75 M D-
mannitol, 1 M GdmCl, 10 µM ThT, HCOOH (pH 3.0) in a 
reaction volume of 28.5 µL per well. To each reaction either 
1.5 µL of serial 10-fold dilutions from 104 to 1015 of the stand-
ard fibril sample (dissolved in HCOOH, pH 3.0) or HCOOH 
(pH 3.0, negative control) was added. Each dilution and the 
control were performed in sixteen technical replica on black 
384-well polystyrene microplates (Corning, Prod. No. 3540) 
covered with sealing tape (Sarstedt, Prod. No. 95.1999). Mi-
croplates were incubated at a constant temperature of 30 °C 
with cyclic agitation (1 min at 300 rpm followed by 2 min 
quiescent) on a SpectraMax Paradigm microplate reader (Mo-
lecular Devices). To monitor the aggregation kinetics, ThT 
fluorescence was measured at 482 nm following excitation at 
440 nm every 3 min using bottom read. The error of the assay 
was calculated from three independent replicate measurements 
of the microplate assay (for data analysis see section ‘Digital 
data analysis’). The replicate measurements are shown in 
Figure 5 and Figure S3. 
Digital data analysis. To digitize the assay readout for ab-
solute propagon quantification, fluorescence endpoint values 
of the amplification reactions were transformed into positive 
and negative signals by thresholding. For the microplate assay, 
the threshold was set five standard deviations above the mean 
of the unseeded negative control reactions (̅ + 5), any 
signal above the threshold was regarded as positive signal. For 
d-AQuA, droplets which showed positive ThT fluorescence at 
the endpoint were scored positive. The fraction of positive 
droplets at every dilution was then calculated from the number 
of positive droplets and the total number of droplets counted in 
the corresponding brightfield images.  The absolute number of 
propagons in both assays was calculated using the Possion 
distribution model. The probability of finding  propagons in a 
reaction compartment if the average number of propagons per 
reaction compartment is , is described by the Poisson distri-
bution 
	
 =  = 	
				
!
	.   (1) 
The probability of having one or more propagons per reaction 
compartment (the probability of a positive signal) is given by 
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  0 = 1  	
 = 0 = 1  		, (2) 
where 	
 = 0 is the probability of not having any propagons 
in the reaction compartment (the probability of a negative 
signal). For the different dilution factors , the probability of 
having one or more propagons per compartment can be 
 
 
Figure 1. D-AQuA workflow. (i) Samples containing 10-fold serial dilutions of the standard fibril sample (blue dashes) are mixed with 
soluble substrate protein and ThT. The mixtures are partitioned into several thousand pL-droplets using a microfluidic flow-focusing de-
vice (inset). (ii) Microdroplets are collected into glass capillaries for endpoint amplification and detection by ThT fluorescence (green). 
(iii) ThT-positive droplets are counted and the absolute number of propagons in the standard fibril sample is quantified by Poisson statis-
tics. 
 
described as 
	
  0 = 1  

 	,   (3) 
where  is the average number of propagons in the original 
sample and  is the dilution factor. The fraction of positive 
signals can be related to the dilution factors using equation 
(3), and therefore the absolute number of propagons in the 
original sample  can be calculated. All data analysis was 
done using Matlab (The MathWorks, USA). 
Fibril quantification by AFM. The number of fibrils per 
unit volume of the standard fibril sample was estimated from 
AFM length distribution and mass conservation. The distri-
bution of fibrils  
! as a function of the contour length 
measured by AFM is shown in Figure 4b. This distribution is 
essentially the same distribution of fibrils per unit volume, 
differing by a mere normalization constant α, so that the 
distribution of fibrils per unit volume is simply # 
!. The 
constant α can be obtained from the total mass per unit vol-
ume, which is obtained from the initial molar concentration 
of monomer $%, i.e. $%&'. Therefore, by mass conserva-
tion this results in 
	
∑# 
! ∙ ! *+,- =	 $%&',  (4) 
where ρ can be taken as the density of the monomer and the 
fibril, supposed to be identical. This then gives 	# = $%&'/

∑ 
! ∙ ! *+,-, since all the terms on the right hand are 
known. 
The total number of fibrils per unit volume, 
01
2
, is then 
	
01
2
= ∑# 
! = # ∑ 
!	 = 	
3456
789:∑0;
<∙<;
∑ 
! , (5) 
where both ∑ 
! ∙ !  and ∑ 
! are known from the 
distribution of fibrils as a function of the contour length in 
Figure 4b. 
 
 
RESULTS AND DISCUSSION 
Workflow of d-AQuA. The set-up of d-AQuA is sche-
matically depicted in Figure 1. We used a microfluidic chip 
with flow focusing geometry to generate uniform droplet 
compartments for highly parallel amplification of single 
propagons in thousands of pL-droplets. This high number of 
parallel measurements enables a digital interpretation of the 
data for precise and accurate quantification of the absolute 
number of propagons contained in a sample. Individual 
droplets encapsulating the soluble substrate protein, Thiofla-
vin T (ThT), a fluorescent dye that allows specific detection 
of amyloid aggregates, along with a series of 10-fold dilu-
tions of a propagon-containing sample, are formed from 
water-in-oil emulsions at kilohertz frequency. Droplets of 
each fibril dilution are stored inside glass capillaries, and 
amplification is carried out in the individual droplets to the 
end-point. Droplets containing amplified aggregates induced 
by propagons are detected by their positive ThT fluorescence 
signals, and the number of fluorescence positive and nega-
tive droplets is counted. As d-AQuA enters a stochastic 
regime at limiting dilutions, the Poisson distribution model 
becomes valid and is applied for determining the absolute 
number of propagons in the original sample. 
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 Standard fibril sample generation. For the development of 
d-AQuA, we used the hormone insulin as amyloid model, 
because it readily forms amyloid fibrils analogous to those of 
disease relevant amyloidogenic proteins38, and is therefore 
widely used as experimental model protein to study amyloid 
formation39-41. We first generated a standard fibril sample, a 
well-characterized sample of preformed insulin fibrils with 
reproducible propagation properties. Insulin fibrils were 
reconstituted in vitro by incubating human insulin at a con-
centration of 1 mM in HCl (pH 2.0) at 65 °C and agitation at 
600 rpm for 72 h. Residual monomeric species were re-
moved by intense washing with 1 mM HCl (pH 2.0) using 
Amicon 
 Figure 2. The standard fibril sample was characterized by DLS 
(a), FTIR spectroscopy (b, shown are the whole spectrum as 
solid line and its deconvoluted peaks in dashed lines), far-UV 
CD spectroscopy (c) and self-propagation activity assay (d). 
centrifugal filters (MWCO 100 kDa)35. The remaining fibrils 
were lyophilized and stored at -20 °C. The fibrils were dilut-
ed to a concentration of 400 µM (monomer equivalents) to 
yield a standard fibril sample. We analyzed this sample for 
the typical morphological and biophysical characteristics of 
amyloid fibrils and its self-propagation activity in a seeded 
propagation assay (Figure 2). Dynamic light scattering 
(DLS) measurements showed that the fibrils have a mean 
hydrodynamic radius of 85 nm (Figure 2a). Furthermore, 
both Fourier transform infrared (FTIR) and circular dichro-
ism (CD) spectra indicated a high β-sheet content of about 
86%, which is characteristic for amyloid fibrils40,42 (Figure 
2b,c). To assess the propagation activity of the sample, the 
kinetics of fibril formation by monomeric insulin in the 
presence of preformed fibrils from the standard sample were 
monitored by optical density at OD370nm (Figure 2d). Increas-
ing concentrations of preformed fibrils (1, 2 and 5% of total 
protein concentration) were found to shorten the lag phase of 
the aggregation reaction gradually, as expected for a nucleat-
ed self-assembly process. These results indicate that the 
standard fibril sample exhibits the typical biophysical char-
acteristics of amyloid fibrils.  
Development of d-AQuA. Next, we established the ex-
perimental conditions for d-AQuA (Figure 1; experimental 
setup in Figure S1). 400 µM insulin in HCl (pH 2.0), 0.1 M 
guanidinium chloride (GdmCl) and 40 µM ThT were encap-
sulated inside microdroplets together with serial 10-fold 
dilutions ranging from 102 to 108 of the standard fibril sam-
ple (in monomer equivalents). We found that the use of a 
high concentration of the substrate and the addition of low 
amounts of GdmCl, which accelerates aggregation by induc-
ing partial unfolding of the monomeric species43, were im-
portant for efficient amplification. Droplets without (i.e. 
unseeded controls) and with different dilutions of preformed 
fibrils were collected in separate capillaries, mounted on a 
microscope slide and heated to 65 °C to accelerate the 
growth and proliferation of the propagons. Fluorescence 
images were taken every 15 min to follow the amplification 
process in the individual droplets over 24 h (Figure 3a,b). 
For the absolute quantification of the number of propagons, 
we analyzed between 500 and 1400 droplets per dilution and 
digitized the readout by grouping the fluorescence endpoint 
signals into positive and negative outcomes by thresholding 
(see Experimental Section for details). A Poisson distribution 
was fitted to the number of fluorescence positive (i.e. propa-
gon containing) droplets for each dilution factor at the assay 
endpoint with the best fits yielding an average number of 
2.1·1011 propagons per µL (accurate to within a factor of 1.1, 
n=2) in the standard fibril sample (Figure 3c and Experi-
mental Section). Moreover, under these conditions we ob-
tained a very low average false positive rate of only ~0.4% 
spontaneously aggregating reactions in a total of about 700 
droplets of the unseeded control (Figure S2). Because of the 
high level of conformity of the data to the Poisson distribu-
tion model, we conclude that the assay is capable of amplify-
ing single propagons in pL droplets and allows the precise 
quantification of absolute numbers of propagons at low 
femtomolar concentrations. 
Validation of the number of propagons by AFM. To 
monitor the number of propagons determined by d-AQuA 
with an alternative method, we used AFM to estimate the 
dimensions and the physical number of fibrillar aggregates 
present in the standard fibril sample (Figure 4a). The average 
contour length of the fibrils was (50 ± 35) nm (Figure 4b) 
and the height was (5.3 ± 1.7) nm (Figure 4c). We used these 
dimensions and mass conservation to calculate the physical 
number of fibrils per unit volume of the standard fibril sam-
ple (see Experimental Section for details). The calculations 
yielded an average number of 1.1·1012 µL-1 fibrils. This 
number is closely similar (less than an order of magnitude, 
i.e. within a factor of ~5) to the number of propagons deter-
mined by d-AQuA (2.1·1011 propagons µL-1). A possible 
explanation for the small difference between these numbers 
might be that not all fibrillar aggregates detected by AFM 
also act as active propagons in d-AQuA. We therefore con-
clude that the active propagons detected by d-AQuA are 
identical to a fraction of morphologically defined fibrillar 
aggregates. 
Comparison to a digital amyloid amplification assay in 
a microplate. Microplate-based amyloid amplification as-
says in 96-well plate formats with an analogue read-out are 
the current standard assays for detecting amyloid aggregates 
in biological samples26,27,34. To enable a direct comparison 
between the sensitivity of this method with d-AQuA, we 
developed an amyloid amplification assay for insulin in a 
microplate with a digital read-out (Figure 5). As the preci-
sion of digital read-outs increases with the number of repli-
cate reactions, we established the assay in a 384-well format. 
We also adapted the experimental conditions to account for 
Page 4 of 9
ACS Paragon Plus Environment
Analytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 the higher volumes and larger surface areas used in the mi-
croplate assay. A range of experimental parameters including 
substrate protein concentration, temperature, shaking cycles, 
pH-value, buffer conditions and additives were systematical-
ly screened and optimized for best assay performance. Espe-
cially crucial was the addition of D-mannitol, which has 
been reported to suppress spontaneous nucleation of insulin 
by stabilization of the monomer, while enhancing the growth 
rate of existing fibrils44. HCOOH at pH 3.0 was chosen as 
the solvent, because of its reported ability to reduce sponta-
neous aggregation of monomeric insulin45. Finally, we iden-
tified a concentration of 2 µM soluble substrate protein in 
0.75 M D-mannitol, 1 M GdmCl, 
 
Figure 3. D-AQuA for single propagon quantification. (a) Representative fluorescence image sections of the capillaries containing micro-
droplets with 10-fold serial dilutions from 102 to 108 of the standard fibril sample (in monomer equivalents). Droplets containing newly 
formed aggregates appeared as ThT fluorescence positive, whereas droplets without preformed fibrils were fluorescence negative. U: 
unseeded control. (b) Representative time courses of insulin fibril formation within microdroplets for different fibril dilutions (colored; 
unseeded controls in black) monitored by ThT fluorescence. 200 representative reactions are shown per dilution. (c) Fraction of fluores-
cence-positive droplets as a function of the logarithm of the dilution factor. Every data point represents the mean ± s.d. from two independ-
ent experiments of d-AQuA. A Poisson distribution (grey line) was fitted to the data to quantify the number of propagons in the standard 
fibril sample.  
10 µM ThT, HCOOH (pH 3.0) with cyclic agitation (1 min 
at 300 rpm, 2 min quiescent) at 30 °C as optimal assay con-
ditions. These conditions resulted in an efficient reduction of 
spontaneous aggregation to a false positive rate of 1 - 2% in 
384 replicas over the course of the experiment (24 h; Figure 
S2), while yielding highly reproducible aggregation kinetics 
of the propagon-catalyzed reactions (Figure 5a).  
For digital quantification of the propagon number in our 
standard fibril sample, we again performed serial 10-fold 
dilutions of the standard fibril sample (104- to 1015-fold 
dilutions in monomer equivalents) using 16 replicas per 
dilution. The aggregation time course was monitored by real-
time ThT fluorescence over 24 h (Figure 5a). At low dilu-
tions (104- to 109-fold), we observed lag times of approxi-
mately 8 h, which gradually increased with higher dilutions 
of preformed fibrils. Endpoint fluorescence signals of reac-
tions with low dilution factors (≤ 109-fold) of preformed 
fibrils were all positive, whereas at higher dilutions only 
fractions of the replicate reactions appeared positive (14, 6 
and 1 out of 16 replicas for 1010-, 1011- and 1012-fold dilu-
tions, respectively). All reactions at dilution factors ≥ 1013-
fold, as well as the control (without preformed fibrils) were 
scored negative (Figure 5b). The fraction of positive signals 
was correlated to the dilution factors, and a Poisson distribu-
tion was fitted to the data (Figure 5c and Experimental Sec-
tion). The best fit yielded an average number of 1.4·109 
propagons µL-1 (accurate to within a factor of 1.2, n=3) in 
the standard fibril sample (Figure 5c and Figure S3). These 
data show that the microplate assay (1.4·109 propagons µL-1) 
is also capable of detecting individual propagons, but when 
compared to d-AQuA (2.1·1011 propagons µL-1) two orders 
of magnitude less propagons were detected. 
The detection of a lower number of active propagons in 
the microplate assay might be attributed to a loss of fibrils to 
various solid surfaces during the extensive pipetting steps or 
to their adherence to the microplate surface. Alternatively, 
the absence of solid contact surfaces in the microdroplets or 
the small droplet sizes, associated with higher effective 
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 concentrations1, might result in a higher number of effective 
propagons. High losses of propagons, however, might signif-
icantly impair the sensitivity and reproducibility of the assay 
and thus lead to an inaccurate quantification of the number 
of propagons. Compared to the microplate assay, d-AQuA 
also exhibited a greatly reduced average false positive rate of 
unspecific amplification reactions in the unseeded control 
(~0.4% compared to 1-2%) and decreased assay time (~8 h 
compared to 24 h). D-AQuA also offers several important 
advantages over the most commonly used amyloid amplifi-
cation assays, PMCA24 and RT-QuIC25,46. First, the ability of 
d-AQuA to perform large numbers of replicate measure-
ments (up to 1400 in d-AQuA compared to typically 3 to 8 in 
PMCA24 and RT-QuIC25,34) yielded highly precise data sets. 
D-AQuA therefore enabled the detection of single propagons 
at the ultimate limit 
 Figure 4. Quantitative AFM measurements. (a) AFM height 
image of preformed insulin fibrils. (b) Histogram of the fibril 
contour length distribution of preformed insulin fibrils. (c) 
Histogram of the average height distribution of the preformed 
insulin fibrils. Data were fitted to a Gaussian distribution (solid 
line) to obtain the means ± s.d. of the contour lengths and the 
fibril heights. 
 
of detection and absolute propagon quantification, whereas 
the concentration in PMCA and RT-QuIC, is typically quan-
tified either in gram or mol or given as amyloid seeding 
activity (SD50) or in tissue dilutions24,25,46 and thus does not 
define the number of propagons. When compared to 
PMCA24, d-AQuA also provided a simpler and faster read-
out by using ThT fluorescence instead of detection by im-
munoblotting. In experiments described in this study, d-
AQuA also showed a significantly decreased assay time (~8 
h compared to typically 1-3 days in PMCA24,46 and RT-
QuIC46), reduced labor-intense and time-consuming pipetting 
steps and associated errors. Moreover, the use of pL-droplets 
instead of µL-volumes significantly reduced the consump-
tion of reagents and, in particular, of the analyte, which is 
crucial, when precious clinical samples with a low concen-
tration of propagons need to be analysed. Hence, d-AQuA 
offers a major improvement over the microplate assays for 
determining exact numbers of propagons, a result that is of 
major importance in the context of ultrasensitive detection 
and precise quantification of the number of low-abundance 
propagons in a given sample.  
 
CONCLUSION 
In conclusion, we present a proof-of-concept method, d-
AQuA, for using digital microfluidics in combination with 
amyloid amplification assays. We used insulin as model 
system and showed that d-AQuA allowed us to run simulta-
neously up to 1400 parallel amplification reactions per fibril 
dilution in pL droplets for extremely accurate and precise 
digital data analysis. Our results showed that d-AQuA ena-
bles the measurement of the activity of single propagons and 
the digital quantification of the absolute number of propa-
gons present in a sample. D-AQuA thus reached the ultimate 
sensitivity limit of detection with the capability to detect a 
single propagon. 
 Figure 5. 384-well microplate assay. (a) Real-time ThT fluo-
rescence time courses of insulin fibril formation with 10-fold 
serial dilutions from 104 to 1015 of the standard fibril sample on 
a microplate (colored; unseeded controls in black). Each dilution 
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 and the control was performed in sixteen technical replica. (b) 
Fluorescence endpoint signals at different fibril dilution factors 
(colored; unseeded controls in black, U). The grey dashed line 
shows the threshold 
=== + 5 used for the positive/negative 
scoring of the signals. (c) Fraction of positive wells as a function 
of the logarithm of the dilution factor. Data represents the mean 
± s.d. from three independent experiments. 
 
Compared to a complementary microplate assay, which also 
reached the ultimate level of sensitivity, d-AQuA turned out 
to be the more rapid and precise method and to have a higher 
recovery rate of low-abundance propagons. This opens up 
the possibility for multiple applications. For example, d-
AQuA provides the potential by correlating its data with 
mathematical models to address specific scientific questions 
for a more fundamental understanding of the molecular 
mechanisms of amyloid formation. In addition, d-AQuA 
might be of practical use for the detection of even smallest 
traces of insulin aggregates that cannot be detected with 
existing analytical methods in biopharmaceutical prepara-
tions of insulin products used for therapy in diabetes pa-
tients47-49 and may lead to an immune response in patients 
after subcutaneous injection49. Our technology also holds the 
potential to be used for rapid, ultrasensitive and highly paral-
lel preclinical and clinical diagnosis through the detection of 
early pathological propagons in protein misfolding and ag-
gregation (PMA) diseases for personalized medicine. In 
particular, a small-volume, single-use disposable chip with 
the ability to diagnose accurately PMA diseases from body 
fluids holds great promise for novel automated diagnostic 
approaches. Finally, the technological innovations of d-
AQuA are well suited to the establishment of powerful high-
throughput screening platforms for the identification of novel 
aggregation inhibitors, both in the context of stabilizing 
reagents for biopharmaceutical products or as drugs to cure 
PMA diseases. We therefore envisage that d-AQuA has great 
potential for advancing biomedical research and sensitive 
point-of-care diagnostics for PMA diseases. 
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